A three-centre experience with adalimumab for the treatment of non-infectious uveitis

British Journal of Ophthalmology

Volumn 97, Issue 2, 2013, Pages 134-138

  Dobner, Bianca Carola ^a,e   Max, Regina ^a   Becker, Matthias D ^a,b   Heinz, Carsten ^c   Veltrup, Ilka ^c   Heiligenhaus, Arnd ^c   Barisani Asenbauer, Talin ^d   Mackensen, Friederike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Triemli Spital ^*  (Switzerland)

^c ST FRANZISKUS HOSPITAL   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Dietrich Bonhoeffer Klinikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CHILD; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FURUNCULOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SLIT LAMP; TREATMENT INDICATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84872975730     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-301401     Document Type: Article

References (23)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmol 2004;111:491-500; discussion 500. (Pubitemid 38293104)
3. Rothova A, Suttorp-van Schulten MS, Treffers WF, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6. (Pubitemid 26113585)
4. Becker MD, Smith JR, Max R, et al. Management of sight-threatening uveitis: new therapeutic options. Drugs 2005;65:497-519. (Pubitemid 40469554)
5. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
6. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35:369-85.
7. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4. (Pubitemid 44799677)
8. Tynjala P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44. (Pubitemid 351267203)
9. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701.
10. Sugar EA, Jabs DA, Altaweel MM, et al. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol 2011;152:1044-52.
11. Suttorp-Schulten MSA, Rothova A. The possible impact of uveitis in blindness, a literature survey. Br J Ophthalmol 1996;80:844-8. (Pubitemid 26345317)
12. Neri P, Lettieri M, Fortuna C, et al. Adalimumab (humira) in ophthalmology: a review of the literature. Middle East Afr J Ophthalmol 2010;17:290-6.
13. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22.
14. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51. (Pubitemid 41117431)
15. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7. (Pubitemid 32952905)
16. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5. (Pubitemid 44468085)
17. Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9:674-83.
18. Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61. (Pubitemid 351733224)
19. Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007;21:824-5. (Pubitemid 46909189)
20. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2011;31:243-5.
21. Suhler E, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12. (Pubitemid 41057986)
22. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
23. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 2010;18:475-81.